Review of idiopathic pulmonary fibrosis diagnosis and management recommendations in Europe

Increased knowledge of Idiopathic Pulmonary Fibrosis (IPF) led to the development of evidence-based diagnosis and treatment guidelines. A 2011 update of the American Thoracic Society and the European Respirato- ry Society, together with the Japanese Respiratory Society ( JRS) and Latin American Thoracic Association (ALAT) provided new guidance on the diagnosis and treatment of IPF. Although the 2011 statement was a major advance, the application of guideline recommendations has identified limitations. The guidelines focus primarily on 'definite' IPF, most of ten diagnosed from typical High-Resolution Computed Tomography (HRCT) appearances. The defi- nition of 'probable' and 'possible' IPF is an advance, but there is a lack of management guidance for these highly preva- lent c linical scenarios. The integration of HRCT and histological data in assigning of diagnostic likelihood is also im- portant, but does not always meet the needs of some patients in whom a multidisciplinary diagnosis of definite IPF should be made. Moreover, the committee did not find sufficient evidence to support the use of any specific phar- macological therapy for patients with IPF. These issues highlight the need for updating available clinical guidelines. Since 2012, several national European recommendations documents and guidelines have been updated. These gen- erally follow the 2011 guidelines, but reflect more recently available c linical study data. Following the publication of the CAPACITY trials showing positive effects of pirfenidone in IPF and its approval in the European Union, many of these updated guideline documents recommend that patients with mild-to-moderate IPF should be offered this therapy. This review analyses the recently developed European country updates, comparing and contrasting recom- mendations on the diagnosis and treatment of IPF.(SarcoidosisVasc DiffuseLung Dis 2013;30:249-261)